nelfinavir + lamivudine + zidovudine

**nelfinavir + lamivudine + zidovudine** is a combination regimen of three antiretroviral drugs used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection[1][2][6]. - **Nelfinavir** is a potent, selective, non-peptidic small molecule inhibitor of HIV-1 protease, thereby blocking the proteolytic cleavage of viral polyproteins and preventing maturation of infectious virions[1]. - **Lamivudine** and **zidovudine** are synthetic nucleoside analogue reverse transcriptase inhibitors (NRTIs). They act by inhibiting the reverse transcriptase enzyme, thereby blocking viral RNA-dependent DNA synthesis, which is essential for HIV replication[3][5]. This triple drug regimen is administered orally and has demonstrated additive or synergistic antiviral activity in vitro and clinical studies. It is primarily indicated for the treatment of HIV-1 infection as part of highly active antiretroviral therapy (HAART)[1][6]. The combination is well tolerated, with minimal additional cytotoxicity compared to monotherapy[1].

Brand names

Combivir (for lamivudine + zidovudine)Viracept + Combivir (sometimes used in combination regimens)

Other names

nelfinavir + lamivudine + zidovudinenelfinavir mesylate + lamivudine + zidovudine